468.00 K
About REMUS PHARMACEUTIC
Sector
CEO
Arpit Deepakkumar Shah
Headquarters
Ahmedabad
Website
Founded
2015
ISIN
INE0O5T01011
FIGI
BBG01GNDCR97
Remus Pharmaceuticals Ltd. operates as a pharmaceutical company. It is engaged in the pharmaceutical business involving marketing, trading and distribution through third party of wide range of pharmaceutical formulations and products manufactured under loan license on contract manufacturing in India as well as in foreign countries. The company was founded by Arpit Deepakkumar Shah and Roma Vinodbhai Shah on September 21, 2015 and is headquartered in Ahmedabad, India.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of REMUS is 7838.40 INR — it has increased by 0.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange REMUS PHARMACEUTIC stocks are traded under the ticker REMUS.
Yes, you can track REMUS PHARMACEUTIC financials in yearly and quarterly reports right on TradingView.
REMUS stock has risen by 26.43% compared to the previous week, the month change is a 39.67% rise, over the last year REMUS PHARMACEUTIC has showed a 358.05% increase.
No, REMUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, REMUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REMUS PHARMACEUTIC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REMUS PHARMACEUTIC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REMUS PHARMACEUTIC stock shows the neutral signal. See more of REMUS PHARMACEUTIC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.